Header Logo

Connection

RADEK SKODA to Thrombocythemia, Essential

Back to Details
This is a "connection" page, showing publications RADEK SKODA has written about Thrombocythemia, Essential.
RADEK SKODA
Connection Strength
4.116
Thrombocythemia, Essential
  1. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023 04 27; 141(17):2127-2140.
    View in: PubMed
    Score: 0.823
  2. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023 04 20; 141(16):1909-1921.
    View in: PubMed
    Score: 0.822
  3. [Myeloproliferative neoplasms - Update on diagnosis and treatment]. Ther Umsch. 2019; 76(9):487-495.
    View in: PubMed
    Score: 0.610
  4. Mutational profile of childhood myeloproliferative neoplasms. Leukemia. 2015 Dec; 29(12):2407-9.
    View in: PubMed
    Score: 0.481
  5. Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia. Blood. 2013 Nov 21; 122(22):3694-6.
    View in: PubMed
    Score: 0.428
  6. Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera. Leukemia. 2025 May; 39(5):1135-1145.
    View in: PubMed
    Score: 0.234
  7. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022 09 13; 6(17):5171-5183.
    View in: PubMed
    Score: 0.197
  8. Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. 2014 Dec; 12(12):2120-30.
    View in: PubMed
    Score: 0.114
  9. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. Blood. 2014 Jun 19; 123(25):3943-50.
    View in: PubMed
    Score: 0.111
  10. Thrombocytosis. Hematology Am Soc Hematol Educ Program. 2009; 159-67.
    View in: PubMed
    Score: 0.076
  11. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008 Apr 15; 111(8):3931-40.
    View in: PubMed
    Score: 0.071
  12. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006 Sep 15; 108(6):1865-7.
    View in: PubMed
    Score: 0.064
  13. The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. Br J Haematol. 1998 Sep; 102(5):1341-3.
    View in: PubMed
    Score: 0.037
  14. Dkk3 levels in patients with myeloproliferative neoplasms. Thromb Res. 2014 Feb; 133(2):218-21.
    View in: PubMed
    Score: 0.027
  15. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009 Nov; 6(11):627-37.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.